Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Somebody is messing with you Mckvee. They sold $15 worth of stock at the end of the day to pay for parking or get a meal at McDonalds. The company is worth more than $.0152 per share. This is not your typical penny stock. Do you see them diluting shares to keep afloat? I know you and many others have been waiting a long time, myself included, but hang in there a little bit longer and make some money on this one.
I tried to buy some more shares as well but Schwab is trying to charge me a $50 fee since it’s international. I miss TD Ameritrade.
Great advice. I’ve been invested since 2020 and keep adding as funds are available but find it difficult not to watch. Hopefully you are correct and we will all be happy in a few months.
Thanks for sharing your questions and Joe’s reply.
He does seem consistent about the timeframe. Throughout the year…
Near future…. In the coming months…
The investors deck states many things will be accomplished in the second and third quarters of this year. I hope he’s correct.
Good luck to us all!
Any luck on a response to your questions?
I initially emailed Investor Relations which is ir@alrt.com
Joe responded and his email address is Joe.stern@alrt.com
He has always been quick to respond.
Good luck and please share if you hear anything worthwhile.
Here is my recent email conversation with Joe Stern. I am still optimistic.
Hello Joe
Is there any chance we get a press release anytime soon? I think it’s been 6 months or more
Joe:
Unfortunately we ran into some last minute manufacturing delays which have pushed out our timeline, nothing to be concerned about long term but that is the reason for the lack of PR’s. We plan on issuing a news release as soon as we can but are waiting to achieve milestones rather than to speak to future plans.
Me:
I know there is progress being made but as an investor sometimes it’s difficult because we don’t get to see any of that. I know you all are investors as well and want success even more than we do
Joe:
We appreciate your understanding, patience and loyalty. I can assure you that in my opinion nothing has changed regarding our potential success this year and what it will translate into from a market perspective. We’re almost there, just a few last hurdles and we’ll have press releases stating achievements not plans or speaking about what is going to happen.
AMEN!!
I still believe…
I too was glad to hear we are still working with Covetrus.
It sounds like we have the right product, manufacturer, and distributor plus an enormous amount of demand for the product. After we get the supply chain issues resolved, we should be selling as much product as we can produce and quickly become cash flow positive. The delays have been frustrating but I think everything is coming together. Only time will tell…
I sent an email to Investor Relations yesterday and I’m sharing their response.
My Questions:
I was checking out the timeline on the company website and it looks like some things got pushed back a quarter. Is there any reason for concern or typical stumbling blocks and production delays?
Also, when can we expect sales information on Canada product launch?
Joe’s Response:
We will be issuing a news release soon to bring investors up to speed on what has, is, and will be occurring. But long story short, as mentioned in previous news releases, during our soft launch in 2023 we ran into complications with the manufacturer so we pulled the product from the market. We had planned to use them until our long term CGM that would also be used for human health was ready for market but due to manufacturing issues regarding yield and capacity combined with the difficulty and expense of using a two piece CGM design we decided to switch to another company as a temporary solution so we could get the product back on the market in early Q3 2023. After many delays and missed deadlines the temporary supplier offered us an interim model to use but we were not satisfied with it and ultimately could not come to an agreement on the original model they offered us or the next generation model they were developing. Because these trials and negotiations took so long we were able to forego the use of any temporary CGM hardware and move forward with our long term model that we are currently using.
The CGM hardware is being manufactured by one of the biggest and most well-known high-tech manufacturers in the world, but we have run into various delays over the past few months because of supply chain issues with materials needed and from adjustments to the hardware, software, and manufacturing line. Whether you’re making 10 or 10,000 units It takes a month to manufacture a batch of CGMs on a production line, a week to ship, and two weeks to test so you can see how the time adds up quickly.
The demand for the GluCurve Pet CGM is staggering, we had over 750 clinics come by our booth at WVC in two and a half days and all of them were interested in ordering. I hope shareholders appreciate that the alternative to a CGM is a glucose curve which most doctors we talked to at WVC flat out will not do and don’t offer because of the expense, unreliable data, and shot duration of readings. While using the human CGM Libre 2 is a big improvement over glucose curves, it is extremely problematic for a number of reasons and veterinarians are truly desperate for a solution that is designed for them which we are offering.
We should start filling Canadian orders in the coming months and then we will be relaunching in the US through Covetrus, EU through Covetrus, and in various other parts of the world direct to market or through local distributors. Lastly, I want to reiterate that neither I, nor others in the company have ever been as excited for the future prospects of ALRT and are working diligently to achieve success for shareholders. As you may know, company insiders are the biggest shareholders so your success and our success are one and the same thing.
V/r
Joe Stern
Head of Animal Health
Joe.Stern@alrt.com
Thanks for sharing. It sounds like things are progressing nicely and the company is finally ready to enjoy the fruits of their hard work over the past few years. I think it’s an exciting time to be an investor. Only time will tell.
I received the email below from Joe Stern:
Long story short, after we spoke in July we experienced some delays with the interim manufacturer and decided to forego releasing the interim GluCurve CGM hardware model in order to move forward with our long term CGM hardware model that we are currently using and will eventually be adapted for human use. I can’t go into the specifics but there are many advantages for ALRT, shareholders, and our customers ranging from higher margins to more advanced hardware and more that will be released in the near future. We believe the current GluCurve CGM hardware model was well worth the delay because it also solves all the many problems of trying to use a human CGM on pets and the popular human CGM being used off label is our only competition if you can call it that.
We have previously announced numbers regarding diabetic pet populations and over the past few years the growth rate of turning to a human CGM to manage diabetic pets has skyrocketed in our estimates due to the desperate need for a better way of monitoring then in-clinic glucose curves.
I hate to sound like a broken record, but we truly believe we are at the finish line and will be releasing Canadian sales information and US relaunch information along with other updates in the coming weeks and over the next month or two. We are also looking at a number of major partnerships with well-known companies that we have placed on the sidelines until we have fully relaunched that we expect to move forward with in Q2-Q3. If you take a look at the updated investor deck you’ll also see that we expect to be cashflow positive in the coming months.
We sympathize with our loyal shareholders especial with the frustration over the low stock price, but we do not believe putting out PRs stating what we will be doing will bring value and have switched to a strategy of announcing what we have completed as opposed to what we have planned. Please be patient over the next month or two and allow us time to show shareholders and the rest of the market what we have been busy executing on.
Please feel free to share this information with fellow shareholders.
V/r
Joe Stern
Head of Animal Health
Joe.Stern@alrt.com
Here is the response I received from Investors Relations asking about company updates...
We hope to put out another update in the coming weeks and if things go as planned I would expect a constant stream of updates going forward. Unfortunately things have taken much longer then we initially anticipated and we have had to overcome several challenges along the way, but I believe we have a better product and better business strategy because of it.
I am personally quite excited for the coming months as a lot of hard work has gone into getting us to where we are now and I believe we’ll finally be able to reap the benefits of our efforts. We greatly appreciate our loyal shareholders and are diligently working to bring them value even if we are not able to publicly announce all of our plans or efforts at this time.
V/r
Joe Stern
Head of Animal Health
It doesn't surprise me that ALRT is not hitting up all the conventions and getting their name and product out there yet. Also, that there are less than 1,000 downloads on google Play and Apple doesn't surprise me either. When Joe Stern responded to me, he talked about a soft launch, and in the December 1, 2022 Press Release, they stated "The quantity of available units will ramp up monthly to support a full U.S. launch followed by a global launch as inventories permit."
Yes, we all want them to roll out the product as quickly as possible; however, it makes sense for them to roll it out as they have product available and not overextend themselves. I think they are ramping up production and controlling the quality while slowly rolling it out. Then, as production capability increases, they will try to create more demand. As a consumer, you don't want to be "sold" a product that is not available yet. Just my opinion.
Things have been pretty quiet so far in 2023 so I asked Investors Relations about any updates they might have in the near future. Their response is below. I like the "very soon" part.
We appreciate your loyalty as a shareholder and are working hard to bring meaningful value to investors, be on the lookout for a press release very soon explaining some of what we have been doing since our soft launch. The response from veterinarians, pet owners, and other animal health companies was fantastic and we are looking forward to a very positive 2023. We are also exploring different partnership opportunities but unfortunately these discussions take time and we cannot comment on them unless a formal agreement is completed and signed.
V/r
Joe Stern
Head of Animal Health
I asked Investors Relations for any updates. Nothing earth shattering but I thought I would share their response.
CES and VMX were both a great success and have brought us exciting opportunities that we are currently exploring, as we have stated in previously new releases there is nothing like the GluCurve Pet CGM on the market for veterinarians and the device and software make monitoring and treating diabetes easier for the doctor, pet parent, and pet. We hope to have numerous updates in the coming months but unfortunately, we cannot share anything publicly at this time.
We appreciate your patience and loyalty as an investor and are working hard to try and bring significant value to shareholders in 2023 and beyond.
V/r
Joe Stern
Head of Animal Health
It’s one thing when ALRT is doing a press release about their own product but when another company is pumped up and promoting our product, it just feels different. I’m excited for our future. Thanks for sharing.
I guess somebody wanted out…
Great news indeed! I hope this Press Release brings on some new investors…
Interesting thing just happened or at least I think its interesting. There was 10,000 shares on the ask at $.06 and I just bought 3,900 of them. Instead of there being 6,100 shares left at $.06, the ask jumped to $.0725. Not that it was a lot of shares but I’m guessing somebody didn’t want to lose the rest of their shares at $.06. When the news we have all been waiting for actually comes out, it won’t matter if we paid $.06, $.07 or $.10, we will all be happy.
Looks like someone wanted to stop the upward momentum and stuck 300,000 shares on the ask.
Yes please take out the 5,000 shares at $.15 then hit the $.28 and make my portfolio look great again…
Here were my questions to Investor Relations and their response:
What is the purpose of the Singapore re-domicile?
As a long time investor, It makes a little nervous that somehow we are going to lose everything when it is finalized.
Also, since all the self-imposed deadlines for manufacturing and distribution agreements keep getting pushed back, it seems like the other investors are losing confidence as well.
What can you do to get the confidence back and increase the share price?
Hello Mr. xxxxxxxx,
The migration to Singapore provides a number of strategic benefits, including better access to government support, investments and funding, partnerships, access to global business, and more. There is no need for concern on the migration, there are currently no plans to go private, in fact quite the opposite. As we have previously announced we are working with the NYSE America to potentially list on their exchange in the near future.
We have outlined our business plan through various new releases and the investor deck on our corporate website, we have been as transparent as we can be at this time about the GluCurve in regard to the market size and need, manufacturing, distribution, and timeline. But we cannot control the price per share of ALRT or the confidence an individual has in our potential future success. We believe by executing on our business plan we will bring long term value to shareholders and that is what we are focused on doing. We have a very strong relationship with our manufacturer, and the global leader in animal health we are working with.
There is not much information we can provide outside of what has been publicly stated, but I would strongly encourage any current or potential shareholder to reread the past handful of new releases and the investors deck on our website before asking themselves, have the recent delays fundamentally changed anything?
V/r
Joe Stern
Head of Animal Health
Joe.Stern@alrt.com
I sent a message to investor relations…
With the commercial launch supposed to be starting in October, will we be hearing about our distribution agreement in the next few days?
Answer from Joe Stern, Head of Animal Health
Unfortunately, we cannot comment on specifics privately. But I can tell you we have a strong relationship with Infinova who manufactures the hardware and with the leading animal health company that we will potentially be completing a distribution agreement with. We are working closely with both parties behind the scenes and will provide more updates to the market in the near future. Thanks for your patience.
Is anyone else hopeful or excited about the next two weeks? After years of waiting we should finally get some game changing news. There has been a lot going on behind the scenes but things are about to get real here. ALRT is the place to be…
I sent a message to investor relations this morning asking about the distribution agreement and within an hour I received a response from Joe Stern, head of animal health.
Joe said, “unfortunately we cannot comment on specifics privately, but be on the lookout for a news release very soon. I can tell you we have a very strong relationship with both Infinovo and our potential distribution partner.”
For whatever it’s worth, I thought I would pass it on…
According to the last press release, One trading week or less until we find out about the distribution agreement. Exciting days ahead for all the shareholders who held on this long.
Agreed. I’m guessing in the next 2 1/2 weeks or less, ALRT will have a third party distribution agreement established which will pay them a large sum of money for a sizable stake in the pet side of the business. The manufacturing agreement is contingent on it being settled by July 31 so it is go time. For me, the big questions are who is the third party and how fast will sales ramp up. I’m cautiously optimistic.
What does it matter if it is a true short squeeze or not? If a bunch of investors want to coordinate their efforts to buy some shares at the same two hour span, why would anyone want to discourage their efforts? Unless they had something to lose by the share price going up....
I can’t imagine the company extending the rights options without giving the shareholders some sort of update. The company has been silent for so long there is no incentive to add additional shares. There has to be an update, right????
$97k bid at .1065 looking strong going into the weekend...
I exercised some of my options for 100k shares today, it’s not a huge discount right now but better than nothing. Also, I would rather the proceeds go to the company than to another investor.
I’m looking forward to some more company news. Hopefully next week when the rights are no longer valid we hear something.
GLTA. Go ALRT!!!!
So true, FORW market value should increase $5 million per .01 increase in the price per share of TSNP since FORW owns warrants to buy 500 million shares on TSNP.
FORW is deeply undervalued at its current share price of about .065. If FORW has no other value other then its shares in TSNP it should be selling at about .17 per share.
TSNP’s 3.9 billion outstanding shares is about 9 times more than FORW’s 440 million shares. TSNP market value is about $625 million vs FORW’s $29 million. If you multiply .125 (500 million/4 billion) times $625 million you get about $78 million. FORW should be selling at about 2.7 times it’s current price or about $.17 per share.
Psychologically it would be difficult to pay more per share then for TMPS but that’s the math. FORW is in a great position to succeed. Hopefully it’s value will get noticed and it’s shareholders will be justly rewarded. GLTA.
$30,000 bid at $.12
Looking strong today...
I’ve only been here a month or two but am very optimistic. I picked up another 50k shares right at the end of the day. GLTA
My rights just showed up on my TD Ameritrade account.
Very frustrating in deed. They seem
To be in control of the price using their hidden shares on the ask. But when they get out of the way, the price soars.
Hi Mary,
Actually for the annual report, I think the company gets 90 days so it could be as late as January 31, 2021. However, last year they filed it on January 17, 2020 and the year before that December 14, 2018, and the year before that on January 31, 2018. You never know for sure when but at least by January 31, 2021.
Great! Thanks for the info.
When do the shareholders get their rights certificates to purchase additional shares? Has anyone seen anything from their broker or the transfer agent or whoever? TIA